Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.

ABSTRACT: Non-small cell lung cancer (NSCLC) represents the paradigm of personalized treatment of human cancer. Several oncogenic druggable alterations have been so far identified, with anaplastic lymphoma kinase (ALK) gene rearrangements being one of the newest and most appealing. Presence of ALK fusions is associated with some particular clinical and pathological features, including a preferential seeding into the central nervous system (CNS). In addition, ALK rearrangements are recognized as the strongest predictor for benefit of anti-ALK therapy. Crizotinib, the first ALK inhibitor (ALK-I) licensed in clinical practice, is the standard of care for newly diagnosed patients. Unfortunately, within the first year of treatment the majority of patients become insensitive to

SUBMITTER: Landi L 

PROVIDER: S-EPMC5233871 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature